Brücke T, Wöber C, Podreka I, Wöber-Bingöl C, Asenbaum S, Aull S, Wenger S, Ilieva D, Harasko-van der Meer C, Wessely P
Neurological University Clinic Vienna, Austria.
J Cereb Blood Flow Metab. 1995 May;15(3):513-8. doi: 10.1038/jcbfm.1995.63.
Twenty-six patients under treatment with the calcium channel blockers flunarizine (Fz) or cinnarizine (Cz) were examined-with single-photon emission computed tomography using [123I]iodobenzamide as a ligand. The striatal dopamine D2 receptor-binding potential was determined and found to be reduced by 14 to 63% (39.5 +/- 15.0%; p < 0.0001) in patients compared with age-matched control values. This reduction was larger in 12 patients with extrapyramidal symptoms and was only slowly reversible after discontinuation of treatment. Patients treated for > 6 months had significantly larger reductions than patients treated for a shorter period. Parkinsonian symptoms were only seen in patients older than 50 years. Our findings prove a neuroleptic-like action of Fz and Cz, which seems to be the major reason for their extrapyramidal side effects. Older age and long-term treatment are predisposing factors for these effects.
对26例正在接受钙通道阻滞剂氟桂利嗪（Fz）或桂利嗪（Cz）治疗的患者，使用[123I]碘苯甲酰胺作为配体进行单光子发射计算机断层扫描检查。测定纹状体多巴胺D2受体结合潜能，发现与年龄匹配的对照值相比，患者的该潜能降低了14%至63%（39.5±15.0%；p<0.0001）。在12例有锥体外系症状的患者中，这种降低幅度更大，且在停药后仅缓慢可逆。治疗超过6个月的患者比治疗时间较短的患者降低幅度显著更大。帕金森症状仅见于年龄超过50岁的患者。我们的研究结果证明Fz和Cz具有类神经安定作用，这似乎是它们锥体外系副作用的主要原因。年龄较大和长期治疗是这些效应的易感因素。
